vs
Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and QIAGEN N.V. (QGEN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $321.1M | — | ||
| Q3 25 | $287.3M | — | ||
| Q2 25 | $212.8M | — | ||
| Q1 25 | $137.3M | — | ||
| Q4 24 | $103.3M | — | ||
| Q3 24 | $62.2M | — | ||
| Q2 24 | $14.6M | — | ||
| Q1 24 | $0 | — |
| Q4 25 | $-58.6M | — | ||
| Q3 25 | $-114.2M | — | ||
| Q2 25 | $-42.3M | — | ||
| Q1 25 | $-73.2M | — | ||
| Q4 24 | $-59.4M | — | ||
| Q3 24 | $-107.0M | — | ||
| Q2 24 | $-152.0M | — | ||
| Q1 24 | $-147.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 96.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -18.6% | — | ||
| Q3 25 | -39.7% | — | ||
| Q2 25 | -22.2% | — | ||
| Q1 25 | -57.8% | — | ||
| Q4 24 | -64.8% | — | ||
| Q3 24 | -187.1% | — | ||
| Q2 24 | -1110.4% | — | ||
| Q1 24 | — | — |
| Q4 25 | -18.2% | — | ||
| Q3 25 | -39.8% | — | ||
| Q2 25 | -19.9% | — | ||
| Q1 25 | -53.4% | — | ||
| Q4 24 | -57.5% | — | ||
| Q3 24 | -172.0% | — | ||
| Q2 24 | -1038.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.55 | — | ||
| Q3 25 | $-5.08 | — | ||
| Q2 25 | $-1.90 | — | ||
| Q1 25 | $-3.32 | — | ||
| Q4 24 | $-2.50 | — | ||
| Q3 24 | $-4.92 | — | ||
| Q2 24 | $-7.10 | — | ||
| Q1 24 | $-7.38 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
